ClinicalTrials.gg
RecruitingNCT02526095FREGATUpdated May 14, 2026

The French EsoGastricTumours Data Base

An observational study in Esophageal Disease, sponsored by University Hospital, Lille. Recruiting at 31 sites in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University Hospital, Lille · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15,000
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This retrospective study aims at evaluating the outcomes of gastrointestinal stromal tumor after surgery.

02

Conditions studied

  • Esophageal Disease

Browse trials for

Keywords

  • Esophagus
  • Surgery
03

In context

Esophageal Diseases

92 studies on the registry are indexed under Esophageal Diseases; 21 are open to participants now.

This study's planned enrollment of 15,000 is above the median of 501 across 24 observational studies indexed under Esophageal Diseases.

Browse Esophageal Diseases studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients with gastroesophageal cancer diagnosed and treatment-naïve, if not receiving neoadjuvant treatment in a participating center will be included after acceptance and signature of consent, whether operated or not, whatever histologic type, tumor stage, and the therapeutic strategy.

Eligibility criteria

Inclusion Criteria: Patient with

  • esophageal cancer, gastric or gastroesophageal junction diagnosed , regardless of the subtype of cancer, tumor stage or treatment envisaged.
  • Naive treatment for this cancer,
  • Naive treatment for this cancer , failing that received treatment ,
  • Male or female ≥ 18 years.
  • social protection scheme .
  • sign a free and for blood sampling , the different questionnaires and the collection of patient information.

Exclusion Criteria:

Male or female aged ( e) under 18 years.

  • Private person of liberty or under supervision (including guardianship ) .
  • People who do not speak French.
  • Major Nobody unable to consent .
  • Patient FREGAT already included in the base.
  • Patient Refusal .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15,000 participants (estimated)
Target follow-up
13 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. DIsease free survival

    Time frame: 5 year disease free survival

Secondary outcomes

  1. overall survival

    Time frame: 5 year overall survival

  2. recurrence rate

    Time frame: 5 year recurrence rate

  3. Total number of patients with complications

    Time frame: from the time between inclusion and occurrence of the event, for the duration of 3 years

  4. Total number of complications

    Time frame: from the time between inclusion and occurrence of the event, for the duration of 3 years

  5. Death

    Time frame: from the time between inclusion and occurrence of the event, for the duration of 3 years

07

Study locations

31 of 31 sites recruiting
08

References and documents

Publications

  • Mariette C, Renaud F, Piessen G, Gele P, Copin MC, Leteurtre E, Delaeter C, Dib M, Clisant S, Harter V, Bonnetain F, Duhamel A, Christophe V, Adenis A; Fregat Working Group. The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers. BMC Cancer. 2018 Feb 6;18(1):139. doi: 10.1186/s12885-018-3991-8. PubMed 29409462 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of May 2027 and a completion of May 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2015
First posted
Aug 18, 2015
Start
Jun 2014
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02526095
Collaborators
French Eso-Gastric Tumors Working Group, National Cancer Institute, France
Responsible party
Sponsor
First posted
Aug 18, 2015
Start date
Jun 2014
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
May 14, 2026

Study contacts

Guillaume Piessen, MD, PhD
Contact
guillaume.piessen@chru-lille.fr
+3320444407
Guillaume Piessen, MD, PhD
study director · University Hospital, Lille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion